Effect of low-dose tamoxifen on benign gynecological and breast conditions in a phase 3 trial in noninvasive breast cancer
Authors:
- Alessio CarboneACAlessio Carbone
- Martino OlivaMOMartino Oliva
- Matteo PuntoniMPMatteo Puntoni
- Aliana Guerrieri-GonzagaAGAliana Guerrieri-Gonzaga
- Irene Maria BriataIBIrene Maria Briata
- Matteo LazzeroniMatteo Lazzeroni
- Davide SerranoDSDavide Serrano
- Livia GiordanoLGLivia Giordano
- Maria DigennaroMDMaria Digennaro
- Laura CortesiLCLaura Cortesi
- Francesco MilloFMFrancesco Millo
- Katia CagossiKCKatia Cagossi
- 29 August 2025
- journal article
- Published by Oxford University Press (OUP) in JNCI: Journal of the National Cancer Institute
- Vol. 118 (6) , 1115-1119
Abstract
Despite the proven efficacy of tamoxifen in breast cancer prevention, its uptake remains limited due to concerns over side effects. A phase 3 trial showed that low-dose tamoxifen (5 mg/d for 3 years) substantially reduces recurrence with minimal toxicity. After 10 years of follow-up, we observed no clinically significant differences in benign gynecological or breast events between the tamoxifen and placebo arms. The uterus was the most frequently affected site (30 cases per arm), followed by the breast (18 cases) and ovary (5 cases vs 3 cases for tamoxifen and placebo, respectively). Endometrial polyps were similarly distributed. Endometrial thickness remained stable in premenopausal women and showed only a mild, non–clinically significant increase in postmenopausal women on tamoxifen (approximately 1.5 mm). Compared with data on standard-dose tamoxifen, rates of benign events were lower. These findings reinforce the favorable safety profile of low-dose tamoxifen.Keywords
Funding Information
- Ministero della Salute (RFPS-2006-1-339898)
- Breast Cancer Research Foundation (PPI-23-002)
- Fondazione AIRC per la ricerca sul cancro ETS (IG 2008)
- Italian League Against Cancer (LILT 7-08)
- Galliera Hospital
This publication has 18 references indexed in Scilit:
- Understanding breast cancer complexity to improve patient outcomes: The St Gallen International Consensus Conference for the Primary Therapy of Individuals with Early Breast Cancer 2023Annals of Oncology, 2023
- Initiation and tolerance of chemoprevention among women with high-risk breast lesions: the potential of low-dose tamoxifenBreast Cancer Research and Treatment, 2022
- Factors affecting uptake and adherence to breast cancer chemoprevention: a systematic review and meta-analysisAnnals of Oncology, 2015
- Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trialThe Lancet, 2014
- A phase-III prevention trial of low-dose tamoxifen in postmenopausal hormone replacement therapy users: the HOT studyAnnals of Oncology, 2013
- Use of tamoxifen and raloxifene for breast cancer chemoprevention in 2010Breast Cancer Research and Treatment, 2012
- Gynecologic conditions in participants in the NSABP breast cancer prevention study of tamoxifen and raloxifene (STAR)American Journal of Obstetrics and Gynecology, 2011
- Benign gynecologic conditions among participants in the Breast Cancer Prevention TrialAmerican Journal of Obstetrics and Gynecology, 2005
- Effects of Tamoxifen on Benign Breast Disease in Women at High Risk for Breast CancerJNCI: Journal of the National Cancer Institute, 2003
- Tamoxifen for Prevention of Breast Cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 StudyJNCI: Journal of the National Cancer Institute, 1998